Objective: We aimed to present our transrec-tal ultrasound (TRUS) guided biopsy results in correlation with prostate specific antigen (PSA), free/total PSA levels, cancer detection rates, Gle-ason scores, cancer ratios of total cores and per-centages in these cores, thus providing informati-on to the literature.
Material and Methods: 184 patients with a mean age of 66 (45-75) underwent TRUS gu-ided biopsy between January 2012 and Novem-ber 2013. The PSA levels were compared with pathological results retrospectively. Patients were grouped according to their PSA levels; PSA levels between 2.5 and 4 ng/ml (Group 1), between 4.1 and 10 ng/ml (Group 2), and >10 ng/ml (Group 3). Patients with PSA levels between 2.5 and 10 ng/ml subdivided into 3 groups according to the-ir free/total PSA levels; <0.1, 0.1-0.25, and >0.25 (Group A,B,C). Prostat cancer (PCA) patients were evaluated with PSA levels and free/total PSA ratios.
Results and Conclusions: In the Group 1 and 3, malignancy rates (%25 and %51.2) were paralel to the literature. In the Group 2 malig-nancy rate was %17.1, and lower than the results in the literature. In Group A and B, malignancy rates (%33 and %20.6) were similar to the litera-ture, while in Group C it was higher (%8.3). We found that the cutoff value of free/total PSA rati-os at 0,12 has a predictive value to dedect clinical important PCA. We suggest that this cutoff va-lue to predict clinical important PCA should be studied in larger randomize controlled series. The prostate cancer ratios in the prostatic biopsy specimen which is firstly used in our study was correlated with the clinically important prostate cancer rates, and tumor volume.
Key Words: Prostate specific antigen, prostate cancer, trans-rectal ultrasound-guided biopsy
Abstract
Objective: We aimed to present our transrec-tal ultrasound (TRUS) guided biopsy results in correlation with prostate specific antigen (PSA), free/total PSA levels, cancer detection rates, Gle-ason scores, cancer ratios of total cores and per-centages in these cores, thus providing informati-on to the literature.
Material and Methods: 184 patients with a mean age of 66 (45-75) underwent TRUS gu-ided biopsy between January 2012 and Novem-ber 2013. The PSA levels were compared with pathological results retrospectively. Patients were grouped according to their PSA levels; PSA levels between 2.5 and 4 ng/ml (Group 1), between 4.1 and 10 ng/ml (Group 2), and >10 ng/ml (Group 3). Patients with PSA levels between 2.5 and 10 ng/ml subdivided into 3 groups according to the-ir free/total PSA levels; <0.1, 0.1-0.25, and >0.25 (Group A,B,C). Prostat cancer (PCA) patients were evaluated with PSA levels and free/total PSA ratios.
Results and Conclusions: In the Group 1 and 3, malignancy rates (%25 and %51.2) were paralel to the literature. In the Group 2 malig-nancy rate was %17.1, and lower than the results in the literature. In Group A and B, malignancy rates (%33 and %20.6) were similar to the litera-ture, while in Group C it was higher (%8.3). We found that the cutoff value of free/total PSA rati-os at 0,12 has a predictive value to dedect clinical important PCA. We suggest that this cutoff va-lue to predict clinical important PCA should be studied in larger randomize controlled series. The prostate cancer ratios in the prostatic biopsy specimen which is firstly used in our study was correlated with the clinically important prostate cancer rates, and tumor volume.
Key Words: Prostate specific antigen, prostate cancer, trans-rectal ultrasound-guided biopsy